Home›Clinical trials›New Jersey

GLP-1 clinical trials in New Jersey: 12 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

12 GLP-1 clinical trials are recruiting at 26 sites in 22 cities across New Jersey. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in New Jersey

  1. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    2 sites in New Jersey

    • Psoriasis Treatment Center of Central New Jersey, East Windsor
    • Care Access - Hoboken, Hoboken. 551-278-8680

    NCT06857942 on ClinicalTrials.gov. See whether you qualify.

  2. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Eli Lilly and Company plans to enroll 4,500 participants.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    5 sites in New Jersey
    • Tandem Clinical Research - Freehold, Freehold
    • Atlantic Health System Morristown Medical Center, Morristown. 973-971-7507
    • Clinical Research of Philadelphia, Pennington. 215-676-6696
    • The Cognitive and Research Center of New Jersey - Ridgewood, Ridgewood. 201-850-4622
    • IMA Clinical Research Warren, Warren Township

    NCT07165028 on ClinicalTrials.gov. See whether you qualify.

  3. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Boehringer Ingelheim plans to enroll 1,800 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    1 site in New Jersey

    • IMA Clinical Research-Warren-69742, Warren Township. 833-602-2368

    NCT06632444 on ClinicalTrials.gov. See whether you qualify.

  1. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Boehringer Ingelheim plans to enroll 1,590 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    1 site in New Jersey

    • IMA Clinical Research-Warren-69742, Warren Township. 833-602-2368

    NCT06632457 on ClinicalTrials.gov. See whether you qualify.

  2. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Eli Lilly and Company plans to enroll 125 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    1 site in New Jersey

    • Hackensack University Medical Center, Hackensack

    NCT06672549 on ClinicalTrials.gov. See whether you qualify.

  3. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Eli Lilly and Company plans to enroll 800 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    1 site in New Jersey

    NCT07153471 on ClinicalTrials.gov. See whether you qualify.

  4. A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

    Phase 3. Vanda Pharmaceuticals plans to enroll 280 participants.

    A study testing whether an investigational medicine from Vanda Pharmaceuticals, tradipitant, can help people reduce nausea and vomiting.

    Who can join. Adults 18 to 65, have nausea and vomiting, BMI 25+.

    1 site in New Jersey

    NCT07446439 on ClinicalTrials.gov. See whether you qualify.

  5. Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

    Phase 2. Rutgers, The State University of New Jersey plans to enroll 40 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, may help during breast cancer treatment.

    Who can join. Adults 18+, have hormone-receptor-positive breast cancer, BMI 27+.

    7 sites in New Jersey
    • Trinitas Comprehensive Cancer Center, Elizabeth. 732-235-3374
    • RWJ Barnabas Health - Robert Wood Johnson University Hospital, Hamilton, Hamilton. 732-235-3374
    • RWJBarnabas Health - Cooperman Barnabas, Livingston, Livingston. 732-235-3374
    • RWJBarnabas Health - Monmouth Medical Center, Long Branch. 732-235-3374
    • Rutgers Cancer Institute, New Brunswick. 732-235-3374
    • RWJBarnabas Health - Newark Beth Israel Medical Center, Newark. 732-235-3374
    • RWJ Barnabas Health - Robert Wood Johnson University Hospital, Somerset, Somerville. 732-235-3374

    NCT06518837 on ClinicalTrials.gov. See whether you qualify.

  6. A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Eli Lilly and Company plans to enroll 240 participants.

    A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    1 site in New Jersey

    NCT06897475 on ClinicalTrials.gov. See whether you qualify.

  7. A Study of a Weight Loss Intervention in People With Endometrial Cancer

    Phase 1. Memorial Sloan Kettering Cancer Center plans to enroll 36 participants.

    A study of a GLP-1 and GIP medicine, tirzepatide, in people with endometrial cancer.

    Who can join. Adults 18+, women only, have endometrial cancer, BMI 25+.

    3 sites in New Jersey

    • Memorial Sloan Kettering Basking Ridge, Basking Ridge. 646-888-5427
    • Memorial Sloan Kettering Monmouth, Middletown. 646-888-5427
    • Memorial Sloan Kettering Bergen, Montvale. 646-888-5427

    NCT06751589 on ClinicalTrials.gov. See whether you qualify.

The other 2 studies recruiting in New Jersey

  1. Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema

    Phase 1. Advanced Reconstructive Surgery Alliance plans to enroll 110 participants.

    A study of a GLP-1 medicine in people with lymphedema.

    Who can join. Adults 18+, have lymphedema, BMI 23+.

    2 sites in New Jersey

    NCT07012642 on ClinicalTrials.gov. See whether you qualify.

  2. A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults

    Phase 1. Shanghai World Leader Pharmaceutical Co., Ltd plans to enroll 60 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lose weight.

    Who can join. Adults 18 to 65, are overweight, BMI 27+.

    1 site in New Jersey

    • Frontage Clinical Services, Inc., Secaucus. 12014167766

    NCT07465965 on ClinicalTrials.gov. See whether you qualify.

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
Written and edited by John SamarasAbout this siteContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.